An electrical & electronics engineer by qualification, Shikha Sinha has been working in the research and content domains for quite a while. Currently penning down informative pieces for page125.org, Shikha is also an active contributor on a variety of business portals spanning healthcare, ICT, renewables, etc. While she isn’t harnessing the power of the pen, Shikha loves to cook, read, and travel. She can be contacted at- [email protected] | https://twitter.com/shikhas999/
Fulcrum plans to initiate a Phase 2b clinical trial in mid-2019 on patients with FSHD in the U.S. and Europe. Fulcrum Therapeutics, a biotechnology firm focused on discovering and developing therapies to rebalance gene expression, has recently announced its exclusive global license agreement with British …
The collaboration specifically focuses on the development, discovery and commercialization for potential new drugs. Under the terms of the agreement, Avidity would receive $20 million in upfront payment and a $15 million investment. Eli Lilly and Company (Lilly), a renowned American pharmaceutical company, has reportedly …
The company now possesses over 91 ANDA approvals, approximately 79 final approvals & 12 tentative approvals, from the FDA. Company shares went up by 1% following the FDA approval of the Teriflunomide tablets. Alembic Pharmaceuticals Ltd (Alembic), a renowned Indian multinational pharmaceutical company, has reportedly …
The new drug would be sold under the brand name Hemlibra in the country It represents an entirely new way to manage Hemophilia A and reviews the standard of care Roche Pharmaceuticals, the Swiss multinational healthcare company, has reportedly announced that it has introduced Emicizumab …
The companies have a total of 10 days to submit their plans for pulling out the products from the market The Food & Drug Administration, a federal agency of the U.S. Department of Health and Human Services, has reportedly ordered Coloplast and Boston Scientific to …
The trial would be funded entirely by MediciNova The result of a successful pivotal trial would lead to the Phase 2b/3 efficacy and safety data support a New Drug Application (NDA) MediciNova, Inc., a biopharmaceutical firm, has reportedly announced that the U.S. Food and Drug …
The portfolio in question includes over 30 generic injectable products. The latest acquisition expands Dr. Reddy’s current portfolio by a considerable margin. Dr. Reddy’s Laboratories Ltd., (Dr. Reddy’s), a renowned Indian multinational pharmaceutical firm based out of Hyderabad, has reportedly entered into a definitive agreement …
The acquisition would be helping Catalent in expanding its capabilities of developing costly & specialized gene therapy treatments. The company would be carrying out the acquisition through an all-cash deal, scheduled to be announced soon. Catalent, Inc., (Catalent), a New Jersey-based technology & pharmaceutical firm, …
Cerner and naviHealth have reportedly expanded their relationship in a bid to introduce new offerings for bundled payments for care improvement advanced (BPCI Advanced) program, projected to support inexpensive and accessible healthcare centered on the patient. As per BPCI Advanced, benefactors prospectively approve a pre-defined …